KalVista Pharmaceuticals creating a new generation of small molecule protease inhibitors for HAE and DME Hereditary Angioedema (HAE)Diabetic Macular Edema (DME)
News KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema Dec 9, 2019 KalVista Pharmaceuticals Reports Fiscal Second Quarter Results Dec 3, 2019 KalVista Pharmaceuticals Provides Business Update Nov 13, 2019 All News
KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema Dec 9, 2019
